Neuroendocrine tumours (NETs) are extremely heterogeneous malignancies marked by their variability in primary site, biological behaviour and the potential production of vasoactive hormones. Multiple systemic options have arisen in the past decade after the publication of positive randomized trials, most recently peptide receptor radionuclide therapy (PRRT/Lutate). However, clinical difficulties remain in terms of sequencing available therapies, and identifying suitable biomarkers to guide treatment selection. This talk will attempt to cover the classification of NETs, the evidence to guide various therapies and the increasing role of PET scans in elucidating tumour biology and driving treatment decisions.